Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 25Recurrence 1Neoplasms 1Neoplasm Metastasis 1Granulosa cell tumor of the ovary 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Cancer Female 1Advanced Breast Carcinoma 1Acrocephalosyndactylia 1

Interventions

Tamoxifen 3Radiotherapy 3Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Radiation 2Observation 2Metformin 2pembrolizumab 1exemestane 1afimoxifene 1Tablets 1Surgical Procedures, Operative 1Steroids 1Specimen Handling 1Protons 1Proton Therapy 1Petrolatum 1Nutrition Assessment 1Neoadjuvant Therapy 1Mastectomy, Segmental 1Mammography 1Magnetic Resonance Spectroscopy 1Letrozole 1Biopsy, Needle 1Biopsy, Large-Core Needle 1Anastrozole 14,17 beta-dihydroxy-4-androstene-3-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Intraductal, Noninfiltrating × exemestane × Clear all
NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡